[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369736-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-369736-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","proteomics-analysis-reveals-fen1-as-a-promising-therapeutic-target-against-small-cell-neuroendocrine-carcinoma-of-the-cervix","Proteomics analysis reveals FEN1 as a promising therapeutic target against small cell neuroendocrine carcinoma of the cervix","","Small cell neuroendocrine carcinoma of the cervix (SCNECC) is a rare, aggressive cervical cancer with poor prognosis. This study investigated molecular drivers of SCNECC progression and identified potential therapeutic targets using proteomic analysis of differentially expressed proteins (DEPs), followed by GO and KEGG enrichment to characterize key pathways. Functional assays (CCK-8, colony formation, cell cycle and apoptosis), qRT-PCR, western blot and immunohistochemistry validated target gene roles. Proteomics detected 2333 DEPs with 2168 upregulated and 165 downregulated proteins. FEN1 was confirmed to be overexpressed, and FEN1 knockdown reduced viability and tumor growth while promoting apoptosis; the FEN1 inhibitor SC13 produced similar effects. FEN1 silencing decreased PIK3CA, PCNA and BCL-2 levels and increased Caspase-9, supporting FEN1 as a promising SCNECC therapeutic target via PCNA regulation.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/proteomics-analysis-reveals-fen1-as-a-promising-therapeutic-target-against-small-cell-neuroendocrine-carcinoma-of-the-cervix/369736/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/proteomics-analysis-reveals-fen1-as-a-promising-therapeutic-target-against-small-cell-neuroendocrine-carcinoma-of-the-cervix/369736.png","ImageObject",300,407,{"name":42,"@type":43},"Stanford","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-21","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What does the study investigate about SCNECC?","Question",{"text":63,"@type":64},"The study explores molecular drivers of SCNECC progression and aims to identify potential therapeutic targets through proteomic analysis and downstream functional validation.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was FEN1 identified as a therapeutic candidate?",{"text":68,"@type":64},"Proteomic profiling revealed many differentially expressed proteins, enrichment pointed to key cellular processes, and immunohistochemistry confirmed FEN1 overexpression; expression and function were further validated with multiple assays.",{"name":70,"@type":61,"acceptedAnswer":71},"What are the effects of reducing or inhibiting FEN1?",{"text":72,"@type":64},"FEN1 knockdown suppresses cell viability, colony formation, and cell cycle while promoting apoptosis and impeding tumor growth in mice. The FEN1 inhibitor SC13 shows similar effects.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},369736,1791706744,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":108,"preview_page_count":33,"preview_urls":145},2336477552062,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nProteomics analysis reveals FEN1 as a promising therapeutic target against small cell neuroendocrine carcinoma of the cervix  \nJianbing Liu1,2,6􀀍, Meiying Zhong1, Kai Yang1, Jinjuan Wang1, Haixia Ma3􀀍, Wei Wang2, Lin Sun5, Lingling Liu4, Jing Xu1, Xiaohua Cui1,6, Jianqing Hao1 & Li Li1  \nSmall cell neuroendocrine carcinoma of the cervix (SCNECC) is a rare, aggressive cervical cancer with poor prognosis. This study explored molecular drivers of SCNECC progression and identified potential therapeutic targets. Proteomic analysis was conducted to identify differentially expressed proteins (DEPs) in SCNECC. Subsequent GO and KEGG enrichment analyses were performed to delineate key  \nDEPs. Functional assays, including CCK-8, colony formation, cell cycle, and apoptosis assays, were conducted to assess the roles of target genes. Expression levels of target genes were validated using qRT-PCR, western blot, and immunohistochemistry (IHC) . Proteomic profiling revealed 2333 DEPsin SCNECC, comprising 2168 upregulated and 165 downregulated proteins. GO and KEGG analyses revealed that the upregulated DEPs were predominantly enriched in processes occurring within the cell nucleus, such as DNA replication, reflecting heightened proliferative activity in SCNECC. IHC confirmed FEN1 overexpression. Functional assays showed that FEN1 knockdown suppressed cell viability, colony formation, and cell cycle, promoted apoptosis, and impeded tumor growth in mice. SC13, a FEN1 inhibitor, also had similar effects. Furthermore, silencing FEN1 markedly reduced PIK3CA, PCNA, and BCL-2 levels, while elevating Caspase-9 expression. CONCLUSION: FEN1 overexpression fuels SCNECC progression via PCNA regulation, positioning FEN1 as a promising SCNECC therapeutic target.  \nKeywords Small cell neuroendocrine carcinoma of the cervix (SCNECC), Proteomic profiling, FEN1 protein, Therapeutic target  \nAbbreviations  \nPCR  \nWB  \nNC SCNECCFEN1  \nDEP  \nPCNA  \nPBS  \nHPV  \nPolymerase chain reaction Western blot  \nNegative control  \nSmall cell neuroendocrine carcinoma of the cervix Flap structure-specific endonuclease 1  \nDifferentially expressed protein Proliferating cell nuclear antigen Phosphate buffered saline Human papilloma virus  \nCervical cancer is the fourth commonly diagnosed cancer (6.8% of 9.7 million new cases) and the fourth leading cause of cancer death (8.1% of 4.3 million deaths) in women all over the world1 and especially among women aged 30 to 44, the incidence rates increased by 1–2% annually2. Small cell neuroendocrine carcinoma of the cervix (SCNECC) represents an exceptionally rare subtype of cervical malignancy, comprising less than1.0% of  \n1School of Basic Medical Sciences, Key Laboratory of Cellular Physiology(Shanxi Medical University, Ministry of Education), Shanxi Medical University, Taiyuan 030001, China. 2Departments of Obstetrics and Gynecology, the Second Hospital of Shanxi Medical University, Taiyuan 036000, China. 3Department of Pathology, Shanxi Province Cancer Hospital, Taiyuan 030013, China. 4Pathology Department, Third Hospital of Shanxi Medical University, Taiyuan 030032, China. 5Shanxi Second People’s Hospital, General Surgery Department, Taiyuan 030012, China.  \n6Shanxi Key Laboratory of Functional Proteins, Shanxi Medical University, Taiyuan 030001, China. 􀀍 email:  \n[liujianbing@sxmu.edu.cn](liujianbing@sxmu.edu.cn); [756985520@qq.com](756985520@qq.com)  \n[www. nature.com/scientificreports/](www. nature.com/scientificreports/)  \nall cervical cancers3. SCNECC is characterized by a markedly aggressive phenotype and an elevated propensity for rapid metastasis compared to other cervical cancer variants4. In the treatment of SCNECC, the traditional approaches such as surgery, radiotherapy and chemotherapy are mainly employed, and currently surgery has relatively good therapeutic effects3. However, 3-and 5-year overall survival rates of SCNECC were only around","cbCailg8K03aKiPJ","https://ap.wps.com/l/cbCailg8K03aKiPJ","pdf",7794681,16,"English","# Introduction\n## SCNECC background and clinical challenges\n## Targeted therapy and unmet needs\n## Rationale for proteomics and omics approaches\n# Results\n## Differentially expressed proteins and enrichment analyses\n## FEN1 overexpression and validation\n## Functional effects of FEN1 knockdown and inhibition in vitro and in vivo\n## Downstream molecular changes and pathway associations\n# Conclusion","[{\"question\":\"What does the study investigate about SCNECC?\",\"answer\":\"The study explores molecular drivers of SCNECC progression and aims to identify potential therapeutic targets through proteomic analysis and downstream functional validation.\"},{\"question\":\"How was FEN1 identified as a therapeutic candidate?\",\"answer\":\"Proteomic profiling revealed many differentially expressed proteins, enrichment pointed to key cellular processes, and immunohistochemistry confirmed FEN1 overexpression; expression and function were further validated with multiple assays.\"},{\"question\":\"What are the effects of reducing or inhibiting FEN1?\",\"answer\":\"FEN1 knockdown suppresses cell viability, colony formation, and cell cycle while promoting apoptosis and impeding tumor growth in mice. The FEN1 inhibitor SC13 shows similar effects.\"}]","Proteomics analysis reveals FEN1 as a promising therapeutic target against small cell neuroendocrine carcinoma of the cervix | PDF",1790184279,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/15629f23a9db41f651c6fac8803ce064.webp",983,1291,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c3811dca292bc16711a4bd2101a6560d.webp",982,1290,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dd36fe1b161d6c1a2fd73f91d33da1a6.webp",981,1289,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d4a4c1fab581f80eab14091a0eaa0801.webp",980,1287]